Chemed Corp. (NYSE:CHE) VP Michael D. Witzeman sold 1,000 shares of Chemed stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $250.00, for a total value of $250,000.00. Following the completion of the sale, the vice president now owns 3,334 shares of the company’s stock, valued at $833,500. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Chemed Corp. (CHE) traded down $1.96 during mid-day trading on Thursday, reaching $238.83. The company’s stock had a trading volume of 80,400 shares, compared to its average volume of 94,341. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. Chemed Corp. has a twelve month low of $150.60 and a twelve month high of $251.00. The stock has a market capitalization of $3,810.00, a PE ratio of 29.65, a P/E/G ratio of 5.09 and a beta of 1.16.
Chemed (NYSE:CHE) last issued its quarterly earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating analysts’ consensus estimates of $2.00 by $0.15. Chemed had a return on equity of 27.69% and a net margin of 4.62%. The firm had revenue of $417.40 million for the quarter, compared to analysts’ expectations of $414.34 million. During the same quarter in the prior year, the firm earned $1.73 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. equities research analysts forecast that Chemed Corp. will post 4.73 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Monday, December 4th. Stockholders of record on Monday, November 13th were given a dividend of $0.28 per share. The ex-dividend date was Friday, November 10th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 0.47%. Chemed’s dividend payout ratio is presently 24.94%.
A number of equities research analysts have weighed in on CHE shares. KeyCorp reiterated a “hold” rating on shares of Chemed in a report on Friday, October 27th. Royal Bank Of Canada restated a “hold” rating and set a $209.00 price objective on shares of Chemed in a report on Tuesday, October 3rd. Zacks Investment Research cut Chemed from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. TheStreet raised Chemed from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Finally, Oppenheimer lifted their target price on Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. Chemed presently has an average rating of “Hold” and a consensus target price of $236.00.
Hedge funds and other institutional investors have recently modified their holdings of the company. Acrospire Investment Management LLC bought a new stake in shares of Chemed during the 2nd quarter valued at $120,000. Pacad Investment Ltd. increased its stake in Chemed by 250.0% in the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after acquiring an additional 500 shares during the last quarter. IFP Advisors Inc increased its stake in Chemed by 1,504.5% in the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after acquiring an additional 662 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Chemed by 12.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after acquiring an additional 83 shares during the last quarter. Finally, MCF Advisors LLC bought a new position in Chemed in the 3rd quarter worth about $152,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Insider Selling: Chemed Corp. (CHE) VP Sells $250,000.00 in Stock” was reported by Stock Observer and is owned by of Stock Observer. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.thestockobserver.com/2017/12/07/insider-selling-chemed-corp-che-vp-sells-250000-00-in-stock.html.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.